Altea Therapeutics and KAI Pharmaceuticals, Inc. Enter into a Preclinical and Clinical Development Agreement for the Transdermal Delivery of Certain Novel KAI Peptides
ATLANTA--(BUSINESS WIRE)--Altea Therapeutics Corporation (“Altea”) announced today that it has entered into a partnership with KAI Pharmaceuticals, Inc. (“KAI”), a drug discovery and development company, for the preclinical and clinical development of certain KAI proprietary peptides utilizing Altea’s proprietary PassPort® Transdermal Delivery System.